Tybourne Capital Management
Tybourne Capital Management is a Hong Kong–based private investment firm founded in 2011 that takes a fundamental approach to global equity investing across public and private markets, with disclosed activity concentrated in healthcare and biotech alongside co-investors such as OrbiMed.
- Company typePrivate
- Founded2011
- HeadquartersHong Kong, Hong Kong SAR China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Tybourne Capital Management does
Tybourne Capital Management is a Hong Kong–domiciled, privately held investment firm founded in 2011 that pursues a fundamental approach to global equity investing across both public and private markets. The firm operates with a lean team of 11–50 employees and is led by co-founders Eashwar Krishnan (Managing Partner and CEO) and Tanvir Ghani (President). Its stated scope spans geographies and capital structures, combining long-only public equity exposure with private equity-style investments.
The firm's most clearly documented strategic activity is concentrated in healthcare/biotech. Tybourne is a major investor in D&D Pharmatech, where it holds a 15% equity stake as the third-largest shareholder alongside specialist investor OrbiMed. In 2025, Tybourne participated in the launch of G-Alpha Therapeutics, a U.S. affiliate of D&D Pharmatech developing alpha radiopharmaceutical therapies for cancer, indicating active cross-border, platform-style deployment of capital in clinical-stage oncology.
As a private asset manager, Tybourne does not publicly disclose AUM, fund count, management fee economics, LP composition, or financial performance. Its revenue mechanics therefore follow the standard investment-management model — management fees on committed or invested capital plus carried interest on fund performance — but with no disclosed magnitudes. No product launches, technology platforms, or operational subsidiaries are documented in the available sources beyond its portfolio holdings.
Tybourne Capital Management firmographics
Firmographics- Name
- Tybourne Capital Management
- Legal name
- Tybourne Capital Management
- Website
- https://tybournecapital.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tybourne Capital Management is a Hong Kong–based private investment firm founded in 2011 that takes a fundamental approach to global equity investing across public and private markets, with disclosed activity concentrated in healthcare and biotech alongside co-investors such as OrbiMed.
- Ownership category
- akta.pro rank
Tybourne Capital Management industry classification
Industry- Product category
- Investment Management
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Mid-Cap Equity (Active) (FSAAAIAB)
- akta.pro secondary industry
- Small-Cap Equity (Active) (FSAAAIAC)
Keywords
Where Tybourne Capital Management is headquartered
LocationHeadquarters
- HQ city
- Hong Kong
- HQ country
- Hong Kong SAR China
- HQ region
- Asia
Markets served
Tybourne Capital Management business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Tybourne Capital Management product offering
Product offeringCore offering
Tybourne Capital Management is a global investment firm that applies a fundamental approach to equity investing across both public and private markets. The firm deploys capital on behalf of investors into equity opportunities worldwide, with operations headquartered in Hong Kong. Its mandate spans public equities and private equity/venture investments, including direct stakes in growth-stage companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Public Equity Investment Management Fundamental long-only and long/short public equity investing service deployed globally on behalf of the firm's investors, applying bottom-up fundamental research to identify equity opportunities.
- Private Equity / Venture Capital Investing Direct private equity and venture capital investment service, taking significant equity stakes in growth-stage companies such as D&D Pharmatech and its U.S. affiliate G-Alpha Therapeutics in the radiopharmaceutical and biopharma sectors.
Companies that use Tybourne Capital Management
Customer profileIdeal customer profiles1 record
Tybourne Capital Management technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tybourne Capital Management partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Tybourne Capital Management competitors and assessment
Company assessmentDirect peers
- Boyu Capital: Asia-focused alternative investment firm with significant private equity and public equity activities. Comparable as an Asia-based, large-scale, fundamental investor operating across capital structures.
- Hillhouse Capital: Asia-headquartered investment firm with a fundamental long-only and private equity mandate. Comparable in geography (Asia base), crossover public/private structure, and fundamental research-driven equity approach.
- PAG (Pacific Alliance Group): Asia-focused alternative investment firm operating private equity, hedge fund, and credit strategies. Comparable as an Asia-headquartered multi-strategy manager with fundamental equity investing capabilities.
- OrbiMed Advisors: Global healthcare-dedicated investment firm across public and private markets. OrbiMed is the most directly comparable peer—it co-invests with Tybourne in D&D Pharmatech and operates an analogous crossover equity mandate focused on life sciences.
- CDH Investments: Hong Kong-based alternative asset manager with both private equity and public market strategies. Highly comparable given shared Hong Kong domicile, Asia focus, and crossover equity investing.
- Sequoia Capital China (HongShan): Asia-based venture and growth equity firm with crossover investments. Comparable as an Asia-focused fundamental investor that blends private and public market exposure.
- Coatue Management: Global crossover fund investing in both public technology equities and private technology companies. Closely comparable crossover public/private fundamental equity model.
Broad incumbents
- Bain Capital: Global alternative asset manager with substantial Asia presence and crossover capabilities. Comparable as a large incumbent with public and private equity strategies, though broader and more diversified than Tybourne.
- Warburg Pincus: Global growth equity investor with significant Asia operations and fundamental equity approach. Comparable as a fundamental, long-duration equity investor across public and private markets, though operating at much greater scale.
- KKR: Global investment firm with active Asia-Pacific private equity and capital markets franchises. Comparable as a scaled incumbent offering crossover exposure, though operating across far more asset classes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Tybourne Capital Management social profiles
Digital presenceTybourne Capital Management financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tybourne Capital Management leadership team
Management profileNumber of profiles
Profiles2 records
Tybourne Capital Management funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tybourne Capital Management M&A and investment
M&A and investmentM&A
Investments30 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tybourne Capital Management
What does Tybourne Capital Management do?
Tybourne Capital Management is a global investment firm that applies a fundamental approach to equity investing across both public and private markets. The firm deploys capital on behalf of investors into equity opportunities worldwide, with operations headquartered in Hong Kong. Its mandate spans public equities and private equity/venture investments, including direct stakes in growth-stage companies.
Is Tybourne Capital Management a public or private company?
Tybourne Capital Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Tybourne Capital Management founded?
Tybourne Capital Management was founded in 2011. It employs 11 to 50 people.
Where is Tybourne Capital Management based?
Tybourne Capital Management is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.
Who are Tybourne Capital Management's main competitors?
Direct peers on record are Boyu Capital, Hillhouse Capital, PAG (Pacific Alliance Group), OrbiMed Advisors, CDH Investments, Sequoia Capital China (HongShan) and Coatue Management. Broad incumbents are Bain Capital, Warburg Pincus and KKR.
Does Tybourne Capital Management have an API?
No public API is recorded for Tybourne Capital Management.
What industry is Tybourne Capital Management in?
Tybourne Capital Management's product category is Investment Management. Its primary akta.pro industry code is FSAAAIAB, Mid-Cap Equity (Active), with a secondary code of FSAAAIAC, Small-Cap Equity (Active). Its NAICS code is 52394 and its SIC code is 6282.